

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on September 27, 2006

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 2829

Patent Application

Docket No. C&R-104

Serial No. 10/538,197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)  
Art Unit : 2829  
Applicants : Richard Joseph Fagan, David Michalovich, Timothy Charles Oliver Nugent  
Serial No. : 10/538,197  
Filed : June 9, 2005  
Conf. No. : 1804  
For : Serine Protease

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313


INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. §371. The applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notification of Acceptance of the Application under 35 U.S.C. 371 (Form PCT/DO/EO/903). The Notification does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of cited references



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                      |
|---|---|----|---|--------------------------|----------------------|
| <b>Substitute for form 1449A/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                      |
|   |   |    |   | Application Number       | 10/538,197           |
|   |   |    |   | Filing Date              | June 9, 2005         |
|   |   |    |   | First Named Inventor     | Richard Joseph Fagan |
|   |   |    |   | Art Unit                 | 2829                 |
|   |   |    |   | Examiner Name            |                      |
| Sheet   | 1 | of | 2 | Attorney Docket Number   | C&R-104              |

| U.S. PATENT DOCUMENTS |                       |   |                                |  |   |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number<br>Number - Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant<br>of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       | U1                    | US-   |                                |  |   |
|                       | U2                    | US-   |                                |  |   |
|                       | U3                    | US-   |                                |  |   |
|                       | U4                    | US-   |                                |  |   |
|                       | U5                    | US-   |                                |  |   |
|                       | U6                    | US-   |                                |  |   |
|                       | U7                    | US-   |                                |  |   |
|                       | U8                    | US-   |                                |  |   |
|                       | U9                    | US-   |                                |  |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |   |                |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|                          | F1                    | WO 02/00860 A2 (on CD)   | 01-03-2002                     | Sugen, Inc.  | All   |                |
|                          | F2                    | WO 00/53756 A2 (on CD)   | 09-14-2000                     | Genentech, Inc.                                    | All   |                |
|                          | F                     |  |                                |  |   |                |
|                          | F                     |  |                                |  |   |                |
|                          | F                     |  |                                |  |   |                |
|                          | F                     |  |                                |  |   |                |
|                          | F                     |  |                                |  |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                      |
|--|---|----|---|--------------------------|----------------------|
| Substitute for form 1449B/PTO<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                      |
|  |   |    |   | Application Number       | 10/538,197           |
|  |   |    |   | Filing Date              | June 9, 2005         |
|  |   |    |   | First Named Inventor     | Richard Joseph Fagan |
|  |   |    |   | Group Art Unit           | 2829                 |
|  |   |    |   | Examiner Name            |                      |
| Sheet  | 2 | of | 2 | Attorney Docket Number   | C&R-104              |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 | R1                    | CALIFF, R.M. <i>et al.</i> "Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial" <i>Circulation</i> , 2000, 101:2231-2238.                  |                |
|                                 | R2                    | Database EMBL "Online!", Database accession no. BQ437135, May 28, 2002 "Agencourt_7826942 NIH_MGC_67 Homo sapiens cDNA clone IMAGE:6152963 5', mRNA sequence".   |                |
|                                 | R3                    | DUFFY, M.J. "Urokinase plasminogen activator and its inhibitor PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies" <i>Clinical Chem.</i> , 2002, 48:1194-1197.  |                |
|                                 | R4                    | VIVIEN, D. and BUISSON, A. "Serine protease inhibitors: novel therapeutic targets for stroke?" <i>J. Cerebral Blood Flow and Metabolism</i> , 2000, 20:755-764.  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |
|                                 | R                     |  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.